Marc A. Pfeffer

TL;DR: It is believed that heart failure should be systematically evaluated in cardiovascular outcome trials of all new glucose-lowering drugs.

TL;DR: Chronic therapy with captopril produced a marked regression of cardiac hypertrophy and prevented the deterioration of cardiac performance in SHR with long-standing hypertension.

TL;DR: This analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit, consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.

TL;DR: Baseline echocardiographic measures of ejection fraction, end-diastolic volume, and infarct segment length were highly predictive of outcomes including total mortality, death or hospitalization for heart failure, or death or any cardiovascular event (heart failure, MI, stroke, resuscitated sudden death), even after adjustment for known covariates.